Interrogating open issues in cancer precision medicine with patient-derived xenografts

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F17%3A00096873" target="_blank" >RIV/00216224:14110/17:00096873 - isvavai.cz</a>

Výsledek na webu

<a href="http://dx.doi.org/10.1038/nrc.2016.140" target="_blank" >http://dx.doi.org/10.1038/nrc.2016.140</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1038/nrc.2016.140" target="_blank" >10.1038/nrc.2016.140</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Interrogating open issues in cancer precision medicine with patient-derived xenografts

Popis výsledku v původním jazyce

Patient-derived xenografts (PDXs) have emerged as an important platform to elucidate new treatments and biomarkers in oncology. PDX models are used to address clinically relevant questions, including the contribution of tumour heterogeneity to therapeutic responsiveness, the patterns of cancer evolutionary dynamics during tumour progression and under drug pressure, and the mechanisms of resistance to treatment. The ability of PDX models to predict clinical outcomes is being improved through mouse humanization strategies and the implementation of co-clinical trials, within which patients and PDXs reciprocally inform therapeutic decisions. This Opinion article discusses aspects of PDX modelling that are relevant to these questions and highlights the merits of shared PDX resources to advance cancer medicine from the perspective ofEurOPDX, an international initiative devoted to PDX-based research.

Název v anglickém jazyce

Interrogating open issues in cancer precision medicine with patient-derived xenografts

Popis výsledku anglicky

Patient-derived xenografts (PDXs) have emerged as an important platform to elucidate new treatments and biomarkers in oncology. PDX models are used to address clinically relevant questions, including the contribution of tumour heterogeneity to therapeutic responsiveness, the patterns of cancer evolutionary dynamics during tumour progression and under drug pressure, and the mechanisms of resistance to treatment. The ability of PDX models to predict clinical outcomes is being improved through mouse humanization strategies and the implementation of co-clinical trials, within which patients and PDXs reciprocally inform therapeutic decisions. This Opinion article discusses aspects of PDX modelling that are relevant to these questions and highlights the merits of shared PDX resources to advance cancer medicine from the perspective ofEurOPDX, an international initiative devoted to PDX-based research.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30204 - Oncology

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2017

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

NATURE REVIEWS CANCER

ISSN

1474-175X

e-ISSN

—

Svazek periodika

17

Číslo periodika v rámci svazku

4

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

15

Strana od-do

254-268

Kód UT WoS článku

000397089500010

EID výsledku v databázi Scopus

—